Successful intraventricular colistin treatment in resistant Klebsiella pneumoniae meningitis

J Infect Dev Ctries. 2022 Jul 28;16(7):1226-1229. doi: 10.3855/jidc.14096.

Abstract

Meningitis due to resistant microorganisms after neurosurgical intervention progresses with significant morbidity and mortality. Treatment is difficult as the antibiotics available for this purpose as well as their transition to the cerebrospinal fluid are limited. Due to the inability of the intravenously administered colistin to cross the blood-brain barrier sufficiently, intraventricular colistin application is recommended in the treatment of meningitis. Herein we report successful treatment with intraventricular colistin of an infant with ventriculoperitoneal shunt-related meningitis due to extended spectrum β-lactamase-producing Klebsiella pneumoniae. The infant lacked clinical response despite effective intravenous antibiotic therapy. Intrathecal/intraventricular colistin can be an effective alternative in the treatment of resistant Gram-negative bacilli meningitis.

Keywords: Klebsiella; antimicrobial resistance; intraventricular colistin; meningitis.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Colistin* / therapeutic use
  • Humans
  • Infant
  • Klebsiella pneumoniae
  • Meningitis* / drug therapy
  • Ventriculoperitoneal Shunt

Substances

  • Anti-Bacterial Agents
  • Colistin